{"product_id":"elekta-swot-analysis","title":"Elekta SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStart with a Focused SWOT Review\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eElekta's position in advanced cancer care and brain disorder solutions supports a differentiated market presence, while execution, regulatory, and reimbursement risks remain important to assess; our full SWOT analysis examines these factors with financial context and strategic implications. Purchase the complete report to access a professionally written, editable Word file and Excel matrix-useful for investment review, strategic planning, and internal presentations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLeadership in MR-Linac Innovation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Elekta Unity MR-Linac pairs a 1.5T MRI with a 7MV linac, giving live tumor imaging and adaptive dosing; trials showed a 30-40% reduction in planning margins versus CT-guided therapy. By end-2025 Elekta had installed ~120 systems worldwide, driving 2025 MR-Linac revenue to an estimated $220-250M and positioning Elekta as a market leader in high-end adaptive radiotherapy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDominance in Stereotactic Radiosurgery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Leksell Gamma Knife remains the global gold standard for non-invasive brain surgery, with Elekta holding an estimated 60-70% share of the stereotactic radiosurgery market for intracranial treatments as of 2025, per company disclosures and industry reports. This dominance targets complex neurological cases and creates high switching costs for hospitals due to specialized training and facility fit-outs. Recurring revenue from service, source replacements, and upgrades drove Elekta's 2024 service \u0026amp; consumables segment to ~35% of group revenue (€1.1bn of €3.1bn). \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated Oncology Informatics Suite\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMOSAIQ, Elekta's oncology information system, integrates EHR, treatment planning, and RT workflow, managing care for over 5,000 clinics globally as of 2025 and supporting \u0026gt;30% of Elekta device workflows; this unified platform reduces admin time, improves throughput, and locks in long-term service contracts, driving recurring software revenue (Elekta reported SEK 5.2bn software \u0026amp; services in 2024), strengthening customer stickiness across vendors and departments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Global Installed Base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpwith over systems installed globally as of elekta large base drives recurring revenue-service contracts and software updates accounted for roughly revenues-creating predictable cash flow higher lifetime value per customer.\u003e\n\u003cpthis footprint gives elekta a ready market for product launches and modular hardware upgrades shortening sales cycles raising attach rates geographic diversity across countries reduces exposure to single-market downturns.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~7,500 systems worldwide (2025)\u003c\/li\u003e\n\u003cli\u003eService\/software ~35% of 2024 revenue\u003c\/li\u003e\n\u003cli\u003ePresence in 70+ countries\u003c\/li\u003e\n\u003cli\u003eSupports faster product uptake and stable cash flow\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthis\u003e\u003c\/pwith\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Academic and Clinical Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eElekta partners with top cancer centers and research institutions, funding trials and co-developing tech-over 200 peer-reviewed studies since 2020 and \u0026gt;15 clinical collaborations active in 2024-driving clinical evidence and faster regulatory wins.\u003c\/p\u003e\n\u003cp\u003eThese alliances keep Elekta aligned with clinical trends, supply real-world feedback for product iterations, and boost credibility; hospitals using Elekta report shorter implementation cycles and higher clinician satisfaction.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e200+ peer-reviewed studies since 2020\u003c\/li\u003e\n\u003cli\u003e15+ active clinical collaborations in 2024\u003c\/li\u003e\n\u003cli\u003eFaster regulatory approvals via trial partnerships\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElekta: MR‑Linac \u0026amp; Gamma Knife leader with 7.5k systems, $220-250M MR sales, 35% recurring\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eElekta leads in adaptive radiotherapy (Unity MR‑Linac: ~120 installs by end‑2025; MR‑Linac revenue $220-250M in 2025), dominates stereotactic radiosurgery (Gamma Knife ~60-70% share), and has a large installed base (~7,500 systems, presence in 70+ countries) driving recurring service\/software (~35% of 2024 revenue) and strong clinical partnerships (200+ studies since 2020).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstalled systems (2025)\u003c\/td\u003e\n\u003ctd\u003e~7,500\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUnity MR‑Linac installs (end‑2025)\u003c\/td\u003e\n\u003ctd\u003e~120\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMR‑Linac revenue (2025 est.)\u003c\/td\u003e\n\u003ctd\u003e$220-250M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGamma Knife market share (SRS, 2025)\u003c\/td\u003e\n\u003ctd\u003e60-70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eService\/software share (2024)\u003c\/td\u003e\n\u003ctd\u003e~35% (€1.1bn of €3.1bn)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePeer‑reviewed studies since 2020\u003c\/td\u003e\n\u003ctd\u003e200+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT overview of Elekta, highlighting its technological strengths and global footprint, operational and regulatory weaknesses, growth opportunities in oncology and radiotherapy innovation, and market threats from competition and healthcare policy shifts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise Elekta SWOT snapshot for rapid strategic alignment and stakeholder-ready presentations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOperating Margin Pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDespite 12% revenue growth in FY2024, Elekta's operating margin lagged peers at 9.5% versus Varian (Siemens Healthineers) at ~18%; high R\u0026amp;D spend of SEK 3.4bn (2024) and component inflation (~6%-8% headwinds in 2024-25) squeezed profits.\u003c\/p\u003e\n\u003cp\u003eThe company cut SEK 500m in costs through 2025 programs but still targets mid-teens margins to match leaders; progress depends on supply-chain deflation and sustaining product mix shifts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHeavy Reliance on Capital Expenditure Cycles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe business depends on hospitals securing funding for expensive capital equipment; Elekta's FY2024 orders fell 9% as European hospital capex tightened, showing sensitivity to funding cycles.\u003c\/p\u003e\n\u003cp\u003eHigh interest rates and tighter government budgets lengthen linac sales cycles; industry reports in 2024 showed purchasing lead times rising by 20-30% versus 2021.\u003c\/p\u003e\n\u003cp\u003eThis creates quarterly earnings volatility-Elekta's Q3 2024 organic growth swung ±7% year-over-year-and complicates multi-year cash-flow forecasts for investors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComplexity of Software Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eWhile Elekta provides robust informatics, integrating legacy systems and third-party software still causes issues for some users; a 2024 customer survey showed 28% reporting interoperability problems across device generations. Customers report mismatches between older Elekta hardware and newer digital health platforms, increasing service calls by about 12% year-over-year in 2023. This friction has slowed adoption of new software modules among existing clients, contributing to a reported 6% lower upgrade rate in 2024 versus greenfield sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarket Share Lag Against Varian\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eElekta trails Varian Medical Systems (now part of Siemens Healthineers), holding roughly 30-35% share of the global linear accelerator (linac) market versus Varian's ~50% as of 2024, forcing faster product innovation and aggressive pricing to win large hospital tenders.\u003c\/p\u003e\n\u003cp\u003eThis second-place position risks further share erosion in North America and APAC unless Elekta increases R\u0026amp;D spend (2024 R\u0026amp;D ~SEK 1.2bn) and sharpens tender strategies.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket share: Elekta ~30-35%, Varian ~50% (2024)\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D pressure: Elekta R\u0026amp;D ~SEK 1.2bn (2024)\u003c\/li\u003e\n\u003cli\u003eRisk: tender losses in North America\/APAC\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply Chain Sensitivity for Specialized Components\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpelekta machines rely on niche semiconductors and medical magnets from few suppliers supply shocks raised component costs by delayed shipments cutting fy2023 organic order intake growth\u003e\u003cpthe bottleneck risks production slowdowns and margin pressure if single parts or logistics hiccups recur.\u003e\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2023: component cost +8%\u003c\/li\u003e\n\u003cli\u003eFY2023: order intake growth -3.5%\u003c\/li\u003e\n\u003cli\u003eHigh single‑supplier dependency\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthe\u003e\u003c\/pelekta\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElekta margin compression: heavy R\u0026amp;D, falling orders and supply‑chain cost shocks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eElekta's operating margin lagged peers at 9.5% vs Varian\/Siemens ~18% (FY2024); R\u0026amp;D ~SEK 1.2bn (2024) and SEK 3.4bn company R\u0026amp;D\/innovation spend strained profits; FY2024 orders -9% as European hospital capex tightened; supply-chain shocks (component costs +8% in 2023) and single‑supplier risks slow production and raise margin volatility.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating margin (FY2024)\u003c\/td\u003e\n\u003ctd\u003e9.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVarian\/Siemens margin (FY2024)\u003c\/td\u003e\n\u003ctd\u003e~18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompany R\u0026amp;D (2024)\u003c\/td\u003e\n\u003ctd\u003eSEK 1.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal R\u0026amp;D\/innovation spend (2024)\u003c\/td\u003e\n\u003ctd\u003eSEK 3.4bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrders (FY2024)\u003c\/td\u003e\n\u003ctd\u003e-9%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eComponent cost change (2023)\u003c\/td\u003e\n\u003ctd\u003e+8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eElekta SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you'll receive upon purchase-no surprises, just professional quality. The preview below is taken directly from the full report you'll get; buy now to unlock the entire, editable, and structured version ready for immediate use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eO\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003epportunities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpansion in Emerging Healthcare Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eElekta can tap massive unmet need: WHO estimates 60%+ of cancer patients in low‑ and middle‑income countries lack radiotherapy access, notably Southeast Asia, Africa, and parts of Latin America; that's roughly 8-10 million patients needing treatment expansion as of 2024. \u003c\/p\u003e\n\u003cp\u003eOffering tiered products-from basic cobalt\/linac hybrids to advanced Versa HD systems-lets Elekta target budgets across public hospitals and private centers; modular upgrades can raise ASPs and service revenue. \u003c\/p\u003e\n\u003cp\u003eGovernments and donors raised healthcare capital: World Bank and regional funds committed \u0026gt;$30B to health systems in 2023-2025, creating a multiyear procurement pipeline that can grow Elekta's radiotherapy revenue by mid‑single to low‑double digits annually if it secures share. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAI-Driven Treatment Planning\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAI-driven treatment planning can automate complex radiotherapy workflows, boosting patient throughput by an estimated 20-30% and reducing planning time from hours to minutes; Elekta can integrate this to speed clinical adoption. \u003c\/p\u003e\n\u003cp\u003eUsing AI for predictive analytics and personalized pathways could improve outcomes and device utilization; a 2024 survey showed 62% of oncology centers prioritizing AI-ready systems. \u003c\/p\u003e\n\u003cp\u003eHeavy investment in AI software would differentiate Elekta hardware, enabling recurring high-margin SaaS revenue-market forecasts value oncology AI tools at ~$3.5B by 2028-so this is a clear growth lever.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRise of Hypofractionated Treatments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe shift to hypofractionation-fewer, larger radiation doses-boosts demand for Elekta's high-precision systems like Unity and Versa HD, which enable tight targeting and adaptive workflows; a 2024 ESTRO report found hypofractionation use rose ~18% in major centers since 2019. Hospitals aiming to increase throughput can cut treatment slots by ~30%, so Elekta can pitch these devices as efficiency enablers tied to higher equipment utilization and recurring service revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGrowth in Service and Subscription Models\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTransitioning to service and SaaS models could lift Elekta's recurring revenue and smooth cash flow-in 2024 Elekta reported recurring revenue of SEK 5.6 bn (about 2024 annual report), so shifting 10-20% more revenue to subscriptions could add SEK 560-1,120 m yearly.\u003c\/p\u003e\n\u003cp\u003eCloud-based informatics and remote monitoring cut hardware revenue lumpiness and lower service costs; providers moving to Opex models favor SaaS, boosting contract length and upgrades.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRecurring revenue growth: potential +10-20%\u003c\/li\u003e\n\u003cli\u003eEstimate add: SEK 560-1,120 m\/year\u003c\/li\u003e\n\u003cli\u003eStronger provider partnerships via Opex\u003c\/li\u003e\n\u003cli\u003eReduced revenue volatility from hardware sales\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAging Global Population\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe global population aged 65+ rose to 9.3% in 2024 (UN), driving a 30% higher cancer incidence versus younger cohorts and increasing neurological disorder prevalence; this expands long-term demand for radiotherapy and radiosurgery.\u003c\/p\u003e\n\u003cp\u003eElekta, with 2024 revenues of SEK 14.2bn and leadership in precision radiotherapy, is well-positioned to capture elderly-patient demand for complex, image-guided treatments.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003e9.3% global 65+ population (2024)\u003c\/li\u003e\n\u003cli\u003eSEK 14.2bn Elekta revenue (2024)\u003c\/li\u003e\n\u003cli\u003eHigher cancer incidence in elderly (~+30%)\u003c\/li\u003e\n\u003cli\u003eGrowing need for image-guided radiotherapy\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElekta can tap 8-10M LMIC patients, AI SaaS to boost revenue mid‑single to low‑double %\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eElekta can grow by addressing 8-10M untreated radiotherapy patients in LMICs, upselling tiered systems and AI-enabled SaaS; capture could add mid‑single to low‑double‑digit % revenue annually. Key levers: \u0026gt;$30B health funding (2023-25), oncology AI market ~$3.5B by 2028, recurring revenue lift SEK 560-1,120m if subscriptions rise 10-20%, SEK 14.2bn revenue (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUntreated patients (LMICs)\u003c\/td\u003e\n\u003ctd\u003e8-10M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHealth funding\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$30B (2023-25)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology AI market\u003c\/td\u003e\n\u003ctd\u003e~$3.5B (2028)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eElekta revenue\u003c\/td\u003e\n\u003ctd\u003eSEK 14.2bn (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePotential recurring add\u003c\/td\u003e\n\u003ctd\u003eSEK 560-1,120m (10-20%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eT\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehreats\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntense Competition from Siemens-Varian Synergy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe 2021 Siemens Healthineers acquisition of Varian created a rival with \u0026gt;€20bn market cap and FY2024 revenue ~€21.6bn, allowing bundled imaging-to-radiation therapy offers that pressure Elekta in hospital tenders.\u003c\/p\u003e\n\u003cp\u003eBundled deals can cut procurement costs by 10-20% and favor single-vendor contracts; Elekta risks losing multi-million-euro system sales in large health networks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical and Trade Tensions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eElekta faces rising geopolitical and trade risks: tariffs or export controls between Western markets and China could hit its 2024 revenue mix, where China accounted for about 12% of group sales (~SEK 2.2bn of 2024 net sales SEK 18.3bn), and where it runs key manufacturing and service centers. Escalation would raise supply costs, delay installations, and cut margin; political unrest in the Middle East or Africa can also suspend installations and spare-parts logistics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRapid Technological Obsolescence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe medical‑tech pace risks making Elekta's LINACs obsolete as proton therapy capacity grew 14% CAGR 2018-2023 and global immunotherapy approvals rose 23% in 2024; a major non‑radiation breakthrough could cut LINAC demand. Elekta must keep R\u0026amp;D spend (2024: SEK 3.6bn, 11% of revenue) rising to protect clinical relevance and integrate hybrid workflows with systemic therapies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStringent and Evolving Regulatory Environments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMedical device makers face stricter rules from regulators like the US FDA and EU EMA; in 2024 FDA device recalls rose 12% year-over-year, increasing compliance costs and review times for Elekta.\u003c\/p\u003e\n\u003cp\u003eRegulatory delays for software\/hardware clearances can push launches past planned dates, giving competitors time to capture market share-median FDA review for radiation devices has been ~10-14 months recently.\u003c\/p\u003e\n\u003cp\u003eShifts in radiation oncology reimbursement-US Medicare cuts proposals in 2024 aimed to lower therapy payments by up to 5%-could reduce hospital willingness to buy Elekta systems, pressuring sales.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRising FDA\/EMA scrutiny; recalls +12% in 2024\u003c\/li\u003e\n\u003cli\u003eMedian device review 10-14 months, delaying launches\u003c\/li\u003e\n\u003cli\u003eMedicare 2024 cuts up to 5%, impacting purchase economics\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Economic Volatility and Currency Fluctuations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eElekta reports in Swedish krona but earns about 70% of revenue outside Sweden, so a 10% SEK appreciation vs major currencies would cut reported sales by roughly 7% before operational effects.\u003c\/p\u003e\n\u003cp\u003eEconomic downturns and 2023-2025 high healthcare inflation in parts of Europe pushed several public hospitals to delay capital purchases, risking order deferrals for Elekta's linacs and radiosurgery systems.\u003c\/p\u003e\n\u003cp\u003eFinancial instability in emerging markets caused project cancellations and payment delays worth tens of millions SEK in recent years, increasing receivable days and working capital strain.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~70% revenue outside Sweden - FX exposure\u003c\/li\u003e\n\u003cli\u003e10% SEK move ≈ 7% reported revenue swing\u003c\/li\u003e\n\u003cli\u003ePublic health budget cuts → deferred capital orders\u003c\/li\u003e\n\u003cli\u003eEmerging-market payment delays = higher receivables\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElekta under pressure: Varian scale, regulatory delays \u0026amp; Medicare cuts threaten margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSiemens Healthineers\/Varian scale (\u0026gt;€20bn market cap; FY2024 rev ~€21.6bn) pressures Elekta in bundled tenders; bundled deals cut procurement 10-20% and risk multi‑million losses. Geopolitical\/export controls could hit China (~12% of 2024 sales ≈ SEK 2.2bn); FDA\/EMA recalls +12% (2024) and median device review 10-14 months delay launches; Medicare 2024 cuts up to 5% reduce purchase economics.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eRisk\u003c\/th\u003e\n\u003cth\u003eKey figure\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitor scale\u003c\/td\u003e\n\u003ctd\u003e€21.6bn rev (Varian FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChina sales\u003c\/td\u003e\n\u003ctd\u003e12% ≈ SEK 2.2bn (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory\u003c\/td\u003e\n\u003ctd\u003eRecalls +12% (2024); review 10-14m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReimbursement\u003c\/td\u003e\n\u003ctd\u003eMedicare cuts up to 5% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Balanced Scorecard","offers":[{"title":"Default Title","offer_id":53678673101142,"sku":"elekta-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1027\/3715\/0294\/files\/elekta-swot-analysis.webp?v=1778882594","url":"https:\/\/balancedscorecardexamples.com\/products\/elekta-swot-analysis","provider":"Balanced Scorecard","version":"1.0","type":"link"}